Latest filings (excl ownership)
10-K
2023 FY
Annual report
16 Apr 24
NT 10-K
Notice of late annual filing
1 Apr 24
8-K
Departure of Directors or Certain Officers
6 Mar 24
8-K
Departure of Directors or Certain Officers
20 Feb 24
8-K
Entry into a Material Definitive Agreement
16 Feb 24
8-K
Departure of Directors or Certain Officers
7 Feb 24
8-K
Changes in Registrant's Certifying Accountant
3 Jan 24
8-K
Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes
7 Dec 23
10-Q
2023 Q3
Quarterly report
20 Nov 23
NT 10-Q
Notice of late quarterly filing
14 Nov 23
EFFECT
Notice of effectiveness
9 Nov 23
CORRESP
Correspondence with SEC
6 Nov 23
UPLOAD
Letter from SEC
3 Nov 23
S-1
IPO registration
31 Oct 23
D
$5.00 mm in equity / options, sold $5.00 mm, 1 investor
3 Oct 23
8-K
Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules
2 Oct 23
424B5
Prospectus supplement for primary offering
2 Oct 23
8-K
Departure of Directors or Certain Officers
6 Sep 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
Regulation FD Disclosure
24 Jul 23
8-K
Entry into a Material Definitive Agreement
21 Jul 23
424B5
Prospectus supplement for primary offering
21 Jul 23
S-8
Registration of securities for employees
14 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
22 Jun 23
8-K
Regulation FD Disclosure
22 May 23
10-Q
2023 Q1
Quarterly report
12 May 23
8-K
Hepion Pharmaceuticals, Inc. Announces Reverse Stock Split
10 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
10-K
2022 FY
Annual report
10 Apr 23
NT 10-K
Notice of late annual filing
31 Mar 23
8-K
Submission of Matters to a Vote of Security Holders
15 Dec 22
DEF 14A
Definitive proxy
21 Nov 22
D
$20.00 mm in equity, sold $20.00 mm, 8 investors
15 Nov 22
10-Q
2022 Q3
Quarterly report
14 Nov 22
PRE 14A
Preliminary proxy
9 Nov 22
8-K
Hepion Pharmaceuticals Announces Pricing of $20.0 Million Private Placement of Convertible Redeemable Preferred Stock
8 Nov 22
8-K
Regulation FD Disclosure
17 Oct 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
Latest ownership filings
4
Michael J. Purcell
7 Mar 24
3
Michael J. Purcell
6 Mar 24
4
Timothy M. Block
21 Feb 24
4
GARY S JACOB
21 Feb 24
4
Kaouthar Lbiati
21 Feb 24
4
JOHN P BRANCACCIO
21 Feb 24
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
4
Peter Wijngaard
28 Nov 23
4
Peter Wijngaard
20 Sep 23
4
Robert T Foster
19 Sep 23
4
Robert T Foster
18 Sep 23
3
Kaouthar Lbiati
20 Jul 22
3
Anand Reddi
5 Jul 22
SC 13G/A
Altium Capital Management LP
14 Feb 22
SC 13G/A
VANGUARD GROUP INC
10 Feb 22
SC 13G/A
Empery Asset Management, LP
19 Jan 22
SC 13G/A
SABBY MANAGEMENT, LLC
4 Jan 22
4
Arnold Lippa
20 May 21
4
Peter Wijngaard
20 May 21
4
GARY S JACOB
20 May 21
4
Robert T Foster
20 May 21
4
John T Cavan
20 May 21
4
JOHN P BRANCACCIO
20 May 21
4
Timothy M. Block
20 May 21
4
THOMAS PHD ADAMS
20 May 21
SC 13G
Altium Capital Management LP
24 Feb 21
SC 13G
SABBY MANAGEMENT, LLC
19 Feb 21
4
Peter Wijngaard
18 Feb 21
4
Robert T Foster
18 Feb 21
4
John T Cavan
18 Feb 21
SC 13G
Empery Asset Management, LP
18 Feb 21
SC 13G/A
CVI Investments, Inc.
16 Feb 21
SC 13G
VANGUARD GROUP INC
10 Feb 21
SC 13G/A
Hudson Bay Capital Management LP
9 Feb 21
SC 13G/A
Empery Asset Management, LP
20 Jan 21
SC 13G/A
SABBY MANAGEMENT, LLC
7 Jan 21
SC 13G/A
HIRSCHMAN ORIN
28 Dec 20
4
Peter Wijngaard
21 Dec 20
SC 13G
HIRSCHMAN ORIN
9 Dec 20
4
Robert T Foster
8 Dec 20